AIM: To investigate patient preferences for clinical attributes of first-line metastatic melanoma treatments. MATERIALS & METHODS: A discrete-choice experiment and best-worst scaling exercise were used to assess relative preferences for treatment attributes. RESULTS: The 200 survey respondents had distinct preferences. Avoiding a 30% risk of colitis or hormone gland problems and avoiding severe fever were more important to respondents than avoiding a 20% risk of extreme sun sensitivity (p < 0.05). Patients preferred taking pills to receiving intravenous infusions in a clinic. When attributes were combined, approximately 85% of respondents preferred a risk profile similar to targeted therapy over a profile similar to immunotherapy, holding efficacy constant. CONCLUSION: Taking patient preferences into account can help patients get the full benefit from metastatic melanoma therapies.
AIM: To investigate patient preferences for clinical attributes of first-line metastatic melanoma treatments. MATERIALS & METHODS: A discrete-choice experiment and best-worst scaling exercise were used to assess relative preferences for treatment attributes. RESULTS: The 200 survey respondents had distinct preferences. Avoiding a 30% risk of colitis or hormone gland problems and avoiding severe fever were more important to respondents than avoiding a 20% risk of extreme sun sensitivity (p < 0.05). Patients preferred taking pills to receiving intravenous infusions in a clinic. When attributes were combined, approximately 85% of respondents preferred a risk profile similar to targeted therapy over a profile similar to immunotherapy, holding efficacy constant. CONCLUSION: Taking patient preferences into account can help patients get the full benefit from metastatic melanoma therapies.
Authors: Daniel Auclair; Carol Mansfield; Mark A Fiala; Ajai Chari; Craig E Cole; Jonathan L Kaufman; Gregory J Orloff; David S Siegel; Jeffrey A Zonder; Brennan Mange; Jennifer Yesil; Mehul Dalal; Joseph R Mikhael Journal: Patient Prefer Adherence Date: 2022-03-01 Impact factor: 2.711